Mycosis fungoides (MF) is a T cell neoplasm with elevation of serum Th2 chemokines. Although interferon-γ (IFN-γ) administration and narrowband-UVB (NB-UVB) phototherapy are used for the treatment of MF, a combination therapy of these two modalities is not fully established.
To define whether the combination of IFN-γ and NB-UVB affects the balance of serum levels of Th1 and Th2 chemokines in patients with MF.
Twelve patients with MF received intravenous or intramuscular injections of recombinant IFN-γ (rIFN-γ) or natural IFN-γ (nIFN-γ) in combination with NB-UVB phototherapy. As control, three MF patients were treated with NB-UVB monotherapy. At the beginning and cessation of therapy, the concentrations of serum Th2 chemokines, TARC/CCL17 and MDC/CCL22, and Th1 chemokines, IP-10/CXCL10 and MIG/CXCL9 were measured by ELISA.
Before treatment, not only Th2 chemokines but also Th1 chemokines were elevated in the patients. Whereas no significant changes were observed in the levels of TARC and MDC, IP-10 and MIG were further elevated by the combination of IFN-γ and NB-UVB. On the other hand, NB-UVB monotherapy did not change the level of either Th1 or Th2 chemokine.
The combination of IFN-γ and NB-UVB elevated serum Th1 chemokines but unaffected Th2 chemokines. Since NB-UVB monotherapy could not affect the chemokine levels, the effect of the combination therapy is attributable to IFN-γ. Given the role of Th1 chemokines for tumor-attacking T cell recruitment at the early stage of MF, the therapy may exert a beneficial effect for early MF.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Dermatological Science
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- WHO-EORTC classification for cutaneous lymphomas.Blood. 2005; 105: 3768-3785
- Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma.J Invest Dermatol. 1994; 103: 669-673
- Differential expression of the HECA-452 antigen (cutaneous lymphocyte-associated antigen, CLA) in cutaneous and non-cutaneous T-cell lymphomas.Histopathology. 1992; 21: 59-64
- The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens.J Invest Dermatol. 1996; 107: 392-397
- Tumor-specific cytotoxic T lymphocyte activity in Th2-type Sezary syndrome: its enhancement by interferon-γ (IFN-γ) and IL-12 and fluctuations in association with disease activity.Clin Exp Immunol. 1998; 112: 403-409
- Phase II study of recombinant human interferon γ (SUN4800) for cutaneous malignancies.Nishinihon Hifuka. 1989; 51: 766-775
- Phase II study of recombinant human interferon γ for treatment of cutaneous T-cell lymphoma.J Natl Cancer Inst. 1990; 82: 208-212
- Action spectrum for phototherapy of psoriasis.J Invest Dermatol. 1981; 76: 359-362
- Narrowband UVB phototherapy for early-stage mycosis fungoides.J Am Acad Dermatol. 2002; 47: 191-197
- Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study.J Am Acad Dermatol. 2003; 48: 215-219
- A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+CCR4+ lymphocytes into lesional atopic dermatitis skin.J Invest Dermatol. 2000; 115: 640-646
- Production of TARC and MDC by naïve T cells in asthmatic patients.J Clin Immunol. 2003; 23: 34-45
- The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4.J Biol Chem. 1997; 272: 15036-15047
- Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4.J Biol Chem. 1998; 273: 1764-1768
- Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes.J Exp Med. 1998; 187: 875-883
- Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3.J Exp Med. 1998; 187: 2009-2021
- Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes.J Exp Med. 1996; 184: 963-969
- Increased CCR4 expression in cutaneous T cell lymphoma.J Invest Dermatol. 2002; 119: 1405-1410
- Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides.J Am Acad Dermatol. 2003; 48: 23-30
- Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides.J Invest Dermatol. 2003; 121: 1045-1052
- The comparison of expression of cutaneous lymphocyte-associated antigen (CLA), and Th1- and Th2- associated antigens in mycosis fungoides and cutaneous lesions of adult T-cell leukemia/lymphoma.Eur J Dermatol. 2003; 13: 553-559
- The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides.Am J Clin Pathol. 2001; 115: 413-421
- CXCR3 and CCR4 double positive tumor cells in granulomatous mycosis fungoides.J Am Acad Dermatol. 2006; 54: 1109-1111
- Chemokine receptor expression in cutaneous T cell and NK/T-cell lymphomas: immunohistochemical staining and in vitro chemotactic assay.Am J Surg Pathol. 2006; 30: 1111-1119
- Treatment with IFN-γ increases serum levels of Th1 chemokines and decreases those of Th2 chemokines in patients with mycosis fungoides.J Dermatol Sci. 2005; 38: 189-195
- Inhibition of T helper 2 chemokine production by narrowband ultraviolet B in cultured keratinocytes.Br J Dermatol. 2007; 156: 830-837
- Immunopathogenesis and therapy of cutaneous T cell lymphoma.J Clin Invest. 2005; 115: 798-812
- Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas.J Am Acad Dermatol. 2002; 46: 95-106
- Narrowband TL-01 phototherapy for patch-stage mycosis fungoides.Arch Dermatol. 2000; 136: 748-752
- The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sezary syndrome.Br J Dermatol. 2003; 148: 709-718
- Epidermal interferon-gamma inducible protein-10 (IP-10) and monokine induced by gamma-interferon (Mig) but not IL-8 mRNA expression is associated with epidermotropism in cutaneous T cell lymphomas.J Invest Dermatol. 1998; 111: 222-226
- Sezary syndrome treated with narrowband ultraviolet B: time-course measurement of serum levels of CCL17/27.Clin Exp Dermatol. 2007; 32: 57-59
Published online: July 12, 2010
Accepted: December 3, 2007
Received in revised form: November 21, 2007
Received: July 28, 2007
© 2007 Japanese Society for Investigative Dermatology. Published by Elsevier Inc. All rights reserved.